VBI Vaccines Inc Hepatitis B Portfolio Discussion Transcript
Okay. Great. Well, as participants are continuing to join, I just want to welcome, everyone, and thank, everyone, for being with us. I'm Steve Seedhouse, biotech analyst at Raymond James, and really is a pleasure to be hosting this presentation and fireside chat with VBI Vaccines. I'll be joined by Jeff Baxter, President and CEO; and David Anderson, Chief Scientific Officer.
This is potentially a really exciting inflection point for the company. I think they've recently presented some intriguing Phase II data for therapeutic hepatitis B vaccine candidate. And now, of course, are also marketing prophylactic HBV vaccine, PreHevbrio, in the US following approval towards the end of 2021. And VBI is also developing, of course, a pipeline of therapeutic and prophylactic vaccines, including a CMV vaccine for glioblastoma or GBM, a pan-coronavirus vaccine. And so we'll discuss all these programs. And at the outset, I think what I want to do is turn it over to the VBI team, who have prepared some slides,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
